Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study

Cortés, Alfonso; López-Miranda, Elena; Fernández-Ortega, Adela; Carañana, Vicente; Servitja Tormo, Sonia; Urruticoechea, Ander; Lema-Roso, Laura; Márquez, Antonia; Lazaris, Alexandros; Alcalá-López,  Daniel; Mina, Leonardo; Gener, Petra; Rodríguez-Morató, Jose, 1987-; Antonarelli, Gabriele; Llombart-Cussac, Antonio; Pérez-García, José; Cortés, Javier

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Cortés, Alfonso
dc.contributor.author López-Miranda, Elena
dc.contributor.author Fernández-Ortega, Adela
dc.contributor.author Carañana, Vicente
dc.contributor.author Servitja Tormo, Sonia
dc.contributor.author Urruticoechea, Ander
dc.contributor.author Lema-Roso, Laura
dc.contributor.author Márquez, Antonia
dc.contributor.author Lazaris, Alexandros
dc.contributor.author Alcalá-López, Daniel
dc.contributor.author Mina, Leonardo
dc.contributor.author Gener, Petra
dc.contributor.author Rodríguez-Morató, Jose, 1987-
dc.contributor.author Antonarelli, Gabriele
dc.contributor.author Llombart-Cussac, Antonio
dc.contributor.author Pérez-García, José
dc.contributor.author Cortés, Javier
dc.date.accessioned 2025-10-22T16:49:19Z
dc.date.available 2025-10-22T16:49:19Z
dc.date.issued 2024
dc.date.updated 2025-10-22T16:49:19Z
dc.description.abstract Purpose: To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline BRCA1/2 mutations (gBRCA1/2mut). Methods: NOBROLA (NCT03367689) is a single-arm, open-label, multicenter, phase IIa trial, enrolling adult patients with advanced TNBC without gBRCA1/2mut and with HRD, who were treated with olaparib. The primary endpoint was clinical benefit rate (CBR) per RECIST v.1.1. Results: Six of 114 patients were eligible and received olaparib. Median follow up was 8.5 months. CBR and overall response rate (ORR) were 50 % (95 % CI, 11.8-88.2). Conclusions: The observed results could prompt further investigation. Trial: ClinicalTrials.gov identifier NCT03367689.
dc.format.mimetype application/pdf
dc.identifier.citation Cortés A, López-Miranda E, Fernández-Ortega A, Carañana V, Servitja S, Urruticoechea A, Lema-Roso L, Márquez A, Lazaris A, Alcalá-López D, Mina L, Gener P, Rodríguez-Morató J, Antonarelli G, Llombart-Cussac A, Pérez-García J, Cortés J. Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study. Breast. 2024 Dec;78:103834. DOI: 10.1016/j.breast.2024.103834
dc.identifier.doi http://dx.doi.org/10.1016/j.breast.2024.103834
dc.identifier.issn 0960-9776
dc.identifier.uri http://hdl.handle.net/10230/71633
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartof Breast. 2024;78:103834
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.keyword Germline BRCA1/2 mutations
dc.subject.keyword Homologous recombination deficiency
dc.subject.keyword Olaparib
dc.subject.keyword PARP inhibitors
dc.subject.keyword Triple-negative breast cancer
dc.title Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)